ArticleHaematologica2023

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma.

Yang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.